QNRX · Quoin Pharmaceuticals, Ltd.

$4.20 -0.09 (-2.10%) At close · Jul 28

Market Cap

$303.67M

72.30M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-07-09	Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome	Event
2026-06-30	Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome	Event
2026-06-23	Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome	Event
2026-06-18	Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003	Event
2026-06-16	Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program	Event
2026-06-04	Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome	Event
2026-06-02	Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome	Event
2026-05-07	Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results	Event
2026-04-30	Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026	Event
2026-04-28	Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs	Event
2026-03-26	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results	Event

Key facts CIK 1671502 CUSIP 74907L409 13F (30d) 2 filings 2 filers Visit website